Ensign Peak Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$201K Hold
5,394
– – ﹤0.01% 1338
2026
Q2
$326K Buy
5,394
+200
+4% +$11.1K ﹤0.01% 1140
2026
Q1
$302K Hold
5,194
– – ﹤0.01% 1123
2025
Q4
$233K Sell
5,194
-10,050
-66% -$422K ﹤0.01% 1240
2025
Q3
$612K Sell
15,244
-10,850
-42% -$382K ﹤0.01% 1299
2025
Q2
$817K Hold
26,094
– – ﹤0.01% 1365
2025
Q1
$875K Hold
26,094
– – ﹤0.01% 1325
2024
Q4
$1.02M Sell
26,094
-136,970
-84% -$5.66M ﹤0.01% 1306
2024
Q3
$6.42M Hold
163,064
– – 0.01% 557
2024
Q2
$6.36M Hold
163,064
– – 0.01% 564
2024
Q1
$7.02M Sell
163,064
-1,316
-0.8% -$60.5K 0.01% 540
2023
Q4
$7.57M Hold
164,380
– – 0.02% 514
2023
Q3
$5.62M Hold
164,380
– – 0.01% 535
2023
Q2
$6.33M Hold
164,380
– – 0.01% 526
2023
Q1
$5.88M Hold
164,380
– – 0.01% 524
2022
Q4
$6.48M Buy
164,380
+50,900
+45% +$1.85M 0.01% 499
2022
Q3
$4.1M Buy
113,480
+57,189
+102% +$2.06M 0.01% 571
2022
Q2
$1.71M Buy
56,291
+47,771
+561% +$1.44M ﹤0.01% 863
2022
Q1
$260K Sell
8,520
-28,595
-77% -$856K ﹤0.01% 1801
2021
Q4
$1.16M Buy
37,115
+5,600
+18% +$167K ﹤0.01% 1199
2021
Q3
$482K Buy
+31,515
New +$548K ﹤0.01% 1631

Other funds holding XENE

Ensign Peak Advisors's XENE Position: Q3 2026 in Review

Ensign Peak Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q3 2026 at 5,394 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Ensign Peak Advisors first reported a position in XENE in Q3 2021 and has held it in 21 quarters since. The position peaked at $7.57M in Q4 2023. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Ensign Peak Advisors held 5,394 shares of Xenon Pharmaceuticals worth $201K as of Q3 2026.
  • Ensign Peak Advisors left its Xenon Pharmaceuticals share count unchanged in Q3 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #1338 holding.
  • Ensign Peak Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
  • Ensign Peak Advisors's Xenon Pharmaceuticals position peaked at $7.57M in Q4 2023.
  • 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.